Insight

Rugengamanzi Eulade: Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era

Photo taken from elevate.in

Jul 5, 2024, 14:21

Rugengamanzi Eulade: Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era

Rugengamanzi Eulade, Oncologist at

“We have published:

‘A comparison of clinical profile and treatment outcome of Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era’ in BMC Cancer.

Highlights

The 2-year OS rate for HIV-HL was 34%, while that for non-HIV-HL was 67%.

Among the HIV-HL patients, predictors of a poorer outcome were a CD4 count ≤ 200 cells/mm3 (P = 0.05), lack of HAART use (P = 0.00), and the use of HAART for ≤ 10 months (P = 0.00).

Conclusion: HIV positivity is still a poor prognostic factor.”

Rugengamanzi Eulade

Additional information.
Source: Rugengamanzi Eulade/LinkedIn

BMC Cancer cancer Christina V. Malichewe Emmanuel L. Lugina Emmanuel Mduma Eulade Rugengamanzi HIV Hodgkin's Lymphoma Mercy M. Mbai OncoDaily Oncology Rugengamanzi Eulade Samuel Thuo

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage